BioStem Technologies Provides Update on the Company’s Form 10 Submission and SEC Review Process

Core Viewpoint - BioStem Technologies, Inc. is progressing towards uplisting to the Nasdaq Capital Market following the anticipated approval of its amended Form 10 by the SEC, which includes audited financial statements for fiscal years 2023 and 2024, and unaudited results for Q1 2025 [2][4]. Group 1: SEC Review Process - BioStem has resolved outstanding SEC accounting comments and plans to file an amended Form 10 by the end of June 2025 [2]. - The company initially submitted its Form 10 in September 2024 and has been collaborating with auditors and the SEC to address accounting treatment questions related to revenue and service fees [3]. - The uplisting is contingent upon the effectiveness of the Form 10 and meeting other Nasdaq listing requirements [3]. Group 2: Company Overview - BioStem is a MedTech company focused on developing, manufacturing, and commercializing placental-derived products for advanced wound care, utilizing its proprietary BioREtain® processing method [6]. - The company’s quality management systems are accredited by the American Association of Tissue Banks and adhere to Good Tissue Practices and Good Manufacturing Processes [7]. Group 3: Leadership and Communication - Jason Matuszewski, BioStem's CEO, expressed optimism about the progress made in the SEC review process and thanked the team for their commitment [4]. - The company encourages stakeholders to stay informed through its distribution list and social media channels [5].